ArticleVaccine2026
Effectiveness of 10-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia and invasive pneumococcal disease among young children in Mozambique.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundMozambique introduced the 10-valent pneumococcal conjugate vaccine (PCV10) in 2013. We aimed to assess PCV10 effectiveness against radiologically confirmed pneumonia (RCP) and invasive pneumococcal disease (IPD) among young children in southern Mozambique.
methodsWe conducted a case-control vaccine effectiveness (VE) study at 2 sites (Mavalane and Manhiça) from January 2014 to December 2016. Children age-eligible to have received PCV10 admitted with pneumonia underwent chest radiograph with standardized interpretation as per the World Health Organization and had nasopharyngeal swabs collected and cultured. IPD cases were recruited in Manhiça only, leveraging existing surveillance; IPD was defined as pneumococcus detected through blood culture or cerebrospinal fluid culture and/or PCR with serotyping by Quellung or PCR. We enrolled age-matched community controls (date of birth ±1 month for cases aged <6 months and +/- 2 months for cases aged ≥6 months). VE was estimated using multivariate logistic regression with 0 doses as a comparator.
resultsAmong 812 enrolled RCP cases, 780 (96.1%) had matched controls. The median age of included cases was 11.6 months and 51.8% were male; 94.4% of cases and 97.0% of controls had ≥1 PCV10 dose. Adjusted VE against RCP was 23.5% (95% confidence interval [95%CI]: -31.9, 55.6) for 2 doses and 47.2% for 3 doses (95%CI: 13.7, 67.7). Adjusted VE of ≥2 doses and exactly 3 doses was 36.8% (95CI%: -11.9, 64.3) and 41.6% (95CI%: -5.7, 67.7), respectively. Models for VE against RCP with PCV10-type carriage yielded negative point estimates with wide confidence intervals. Among 26 enrolled IPD cases, 24 (92.3%) had matched controls (including 8 PCV10-type cases); 91.7% of IPD cases and 100% of controls had ≥1 PCV10 dose. IPD VE models did not converge.
conclusionPCV10 offers substantial protection against RCP in young children in a high burden setting, highlighting its importance for reducing child pneumonia globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.